CurrentCignaPolicy IP0544

Pyridostigmine 30 mg tablet — Medical Necessity Criteria

Medical necessity criteria and coverage guidance for pyridostigmine 30 mg tablets for treatment of myasthenia gravis under Cigna-administered health benefit plans.

Policy Summary

PayerCigna

PolicyPyridostigmine 30 mg tablet — Medical Necessity Criteria

Policy CodePolicy IP0544

Change TypeNo material changes

Effective Date

Next Review Date

Key ActionObtain prior authorization and document diagnosis of myasthenia gravis plus documented inability to use pyridostigmine 60 mg scored tablet.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

30 mgtablet strength addressed

myasthenia gravisindication covered when criteria met

12 moauthorization duration

60 mg tabletrequired documented inability

Coverage Criteria

Initial Approval Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial Approval Criteria: Individual has myasthenia gravis AND documented inability to use pyridostigmine 60 mg scored tablet.documented inability to use 60 mg scored tablet

When coverage is available and medically necessary, dosage, frequency, duration of therapy, and site of care should be reasonable, clinically appropriate, and supported by evidence-based literature and adjusted based upon severity, alternative available treatments, and previous response to therapy.

Product & Coding

Covered product (by description)mixedCovered

pyridostigmine 30 mg tablet

Product and strength referenced in policy

Documented inability to use alternative formulation

ThresholdDocumented inability to use pyridostigmine 60 mg scored tablet

ContextRequired for initial approval of pyridostigmine 30 mg tablet for treatment of myasthenia gravis

Documentation expectationMedical record must note reason the 60 mg scored tablet cannot be used (e.g., intolerance, inability to swallow scored tablet)

Provider Actions & Authorization

Prior Authorization

Prior authorization required; approvals up to 12 months

Prior authorization is required for pyridostigmine 30 mg tablet and, when approved, initial and reauthorization approvals may be authorized for up to 12 months. Approval for initial therapy requires documented inability to use pyridostigmine 60 mg scored tablet.

Step Therapy

Step requirement: must document inability to use 60 mg scored tablet

Coverage of the 30 mg tablet is conditioned on a documented inability to use the 60 mg scored tablet — a step to the 60 mg product is implied before approval of the 30 mg tablet.

Documentation Required

Required documentation for initial and continuation requests

Documentation must include a diagnosis of myasthenia gravis and a documented inability to use pyridostigmine 60 mg scored tablet; for continuation requests, include prior approval information and evidence of a beneficial response to pyridostigmine 30 mg tablet.

Denial Risk

Non-covered uses: indications other than myasthenia gravis

Use of pyridostigmine 30 mg tablet for any indication other than treatment of myasthenia gravis is considered experimental, investigational or unproven and may be denied.

Background

Pyridostigmine is an acetylcholinesterase inhibitor indicated for the treatment of myasthenia gravis (MG). It is commonly used as initial symptomatic therapy in patients with MG to improve neuromuscular transmission and reduce muscle weakness.

Clinical guidance supports pyridostigmine as part of initial management for most individuals with MG, often alongside or prior to immunomodulatory therapies; non‑covered indications (for example, pretreatment for certain military exposures) are outside routine clinical coverage considerations.

Definitions & Clinical Context

Myasthenia gravis (MG) treatment context

IndicationMyasthenia gravis — pyridostigmine is indicated for treatment of MG

Role in therapyPyridostigmine is commonly used as initial symptomatic therapy for most individuals with MG

Guideline supportAAN and International Consensus Guidance recommend pyridostigmine as part of initial treatment for most patients with MG; escalate to corticosteroids or immunosuppressives if treatment goals are not met

Policy scopeCoverage of pyridostigmine 30 mg tablet is limited to treatment of myasthenia gravis when criteria are met